CD38 and neoplasm: ,11 Surprisingly, analysis of transcriptional data in CoMMpass demonstrate that increased tumor CD38 expression at diagnosis was not associated with improved outcomes in patients treated with daratumumab later in their clinical course (supplemental Figure 6).